Novavax vaccine demonstrates 90% efficacy, 100% protection against moderate, severe disease

The US company Novavax said that its COVID-19 vaccine, in the Phase 3 trial, demonstrated an overall efficacy of 90.4 percent against mild, moderate, and severe disease caused by the COVID-19 strain. "Novavax COVID-19 Vaccine demonstrates 90% overall efficacy and 100% protection against moderate and severe disease in PREVENT-19 Phase 3 Trial," the company said in a tweet. Also Read | Coronavirus: India reports 70,421 new cases in 24 hours; lowest after 74 days While releasing its Phase 3 trial details, the company said that the preliminary safety data from PREVENT-19 showed the vaccine to be generally well-tolerated. Serious and severe adverse events were low in number and balanced between vaccine and placebo groups, it said, adding that no single adverse event term was reported by more than 1 percent of participants. Also Read | US FDA rejects emergency use authorisation for Bharat Biotech’s vaccine Covaxin

PREVENT-19 Phase 3 Trial, Novovax COVID-19 Vaccine Candidate Demonstrates:

• 90% overall efficacy
• 93% efficacy against predominantly circulating Variants of Concern and Variants of Interest
• 91% efficacy in high-risk populations
• 100% protection against moderate and severe disease
• 100% efficacy against variants "not considered Variants of Concern/Interest"

Stanley C. Erck, President and Chief Executive Officer, Novavax, said that "Novavax is one step closer to addressing the critical and persistent global public health need for additional COVID-19 vaccines." Biotech firm is planning to file for authorisation with the Food and Drug Administration in the third quarter of 2021. Click here to follow PTC News on Twitter -PTC News